Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2500
Single User License Price INR 175000
Corporate User License Price USD 7500
Corporate User License Price INR 525000
Site License Price USD 5000
Site License Price INR 350000
Request a Quote

Report Title

KOL Perspectives: Rituximab Use in Lupus

Quote Request for License Type
License Type Price  
Single User License USD 2500
Site License USD 5000
Enterprise Wide License USD 7500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

KOL Perspectives: Rituximab Use in Lupus


Quote Request for License Type
License Type Price  
Single User License USD 2500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

KOL Perspectives: Rituximab Use in Lupus

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

KOL Perspectives: Rituximab Use in Lupus



Executive Summary

KOL Perspectives: Rituximab Use in Lupus

Summary

This KOL Insight briefing focuses on KOLs views of Rituximab Use in Lupus.

Questions topics-

- Current & future use of RTX in lupus

- Views on RTX's Phase II/III EXPLORER trial re-analysis

- Opinion on data demonstrating that RTX is effective for the management of refractory SLE

- Views on data from the Phase II SYNBIoSe study assessing RTX + BEL combination therapy

- Lupus patients most suitable for RTX + BEL combination therapy

- Use of RTX + BEL combination therapy

Key Highlights

- Most US KOLs stated that future launch of biosimilar RTX will have no impact on their overall use of RTX, but uptake will depend on price

- Most KOLs highlighted that the level of background medication used in the EXPLORER trial was too high and consequently impeded results

- Most KOLs flagged that payers may be a barrier to combination therapy use, especially given the lack of approval for RTX in lupus.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our Lupus key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Q2 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Rituximab Use in Lupus

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Roche

GSK

Rituximab, lupus, biosimilar, combination therapy


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person